TRIM21 and interstitial lung disease: Higher disease activity at baseline, presence of Raynaud’s phenomenon, anti-Ro52 autoantibodies (either isolated or combined with anti-Ro60), hypergammaglobulinemia, RF and C4 hypocomplementemia were identified as predictive factors for future ILD development.